Article Text
Abstract
All neurologists need to be able to recognise and treat cerebral venous thrombosis (CVT). It is difficult to diagnose, partly due to its relative rarity, its multiple and various clinical manifestations (different from ‘conventional’ stroke, and often mimicking other acute neurological conditions), and because it is often challenging to obtain and interpret optimal and timely brain imaging. Although CVT can result in death or permanent disability, it generally has a favourable prognosis if diagnosed and treated early. Neurologists involved in stroke care therefore also need to be aware of the treatments for CVT (with varying degrees of supporting evidence): the mainstay is prompt anticoagulation but patients who deteriorate despite treatment can be considered for endovascular procedures (endovascular thrombolysis or thrombectomy) or neurosurgery (decompressive craniotomy). This review summarises current knowledge on the risk factors, diagnosis, treatment and prognosis of CVT in adults, and highlights some areas for future research.
- Amyloid
- cerebrovascular disease
- MRI
- stroke
This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the COVID-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
https://bmj.com/coronavirus/usageStatistics from Altmetric.com
Footnotes
LU and MS contributed equally
Contributors LU and MS prepared the first draft with DJW. HC, PC and DJW reviewed the manuscript for intellectual content. DJW and PC prepared the figures.
Funding DJW receives research funding support from the British Heart Foundation and the Stroke Association. This work was undertaken at University College London Hospitals NHS Foundation Trust/University College London, who received a proportion of funding from the Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme.
Competing interests DJW has received honoraria from Bayer, Portola and Alnylam, outside the submitted work.
Patient consent for publication Not required.
Provenance and peer review Commissioned; externally peer reviewed by José Ferro, Lisbon, Portugal, and Teddy Wu, Christchurch, New Zealand.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Other content recommended for you
- Current endovascular strategies for cerebral venous thrombosis: report of the SNIS Standards and Guidelines Committee
- Time to recanalisation in patients with cerebral venous thrombosis under anticoagulation therapy
- Dural arteriovenous fistulas as a cause of intracranial hypertension due to impairment of cranial venous outflow
- Cerebral venous thrombosis: comparing characteristics of infective and non-infective aetiologies: a 12 - year retrospective study
- Intracranial venous collaterals in cerebral venous thrombosis: clinical and imaging impact
- Headache as the only neurological sign of cerebral venous thrombosis: a series of 17 cases
- The woman without a history
- Acute subdural haemorrhage complicating cerebral venous thrombosis in a patient with protein C deficiency
- Suspected adverse reaction to compounded preparations prescribed for weight loss: two cases of cerebral venous thrombosis
- Rapidly expanding venous intracerebral haemorrhage with spot sign